ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROMES IN CHILDREN: A Report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON)

REFERENCES

• Hasle H. Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr. 2007; 19: 1–8
   PubMedGoogle Scholar
• Hasle H, Niemeyer C M, Chessells J M, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277–282
   PubMed Web of Science ®Google Scholar
• Barnard D R, Lange B, Alonzo T A, et al. Acute myeloid leukaemia and myelodysplastic syndrome in children treated for cancer: Comparison with primary presentation. Blood 2002; 100: 427–434
   PubMedGoogle Scholar
• Woodward P, Barfield R, Hale G, et al. Outcome of hemopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukaemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006; 47: 931–935
   PubMedGoogle Scholar
• Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: A retrospective study of 189 patients in Japan. Leukemia 2001; 15: 1713–1720
   PubMedGoogle Scholar
• Woods W G, Barnard D R, Alonzo T A, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukaemia or myelodysplastic syndrome: A report from the Children's Cancer Group. J Clin Oncol 2002; 20: 434–440
   PubMedGoogle Scholar
• Yusuf U, Fragoul H A, Gooley T A, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: The Seattle experience. Bone Marrow Transplant 2004; 33: 805–814
   PubMed Web of Science ®Google Scholar
• Trobaugh-Lotrario A D, Kletzel M, Quinones R R, et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): Successful management by allogeneic hemopoietic stem cell transplant (HSCT). Bone Marrow Transplant 2005; 35: 143–149
   PubMedGoogle Scholar
• Bader P, Hoelle W, Klingebiel T, et al. Quantitative assessment of mixed hematopoietc chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res. 1996; 16: 1759–1763
   PubMed Web of Science ®Google Scholar
• Sullivan K M. Graft versus host disease. Hematopoietic Cell Transplantation, E D Thomas, K G Blume, S S Forman. Blackwell Scientific, Malden, MA 1999; 513–536
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1957; 53: 457–481
   Web of Science ®Google Scholar
• Stary J, Locatelli F, Niemeyer C M. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant 2005; 35(Suppl 1)S13–S16
   Google Scholar
• de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620–630
   PubMed Web of Science ®Google Scholar
• Kardos G, Baumann I, Passmore J, et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102: 1997–2003
   PubMed Web of Science ®Google Scholar
• Bader P, Niemeyer C, Willasch A, et al. Children with myelodysplastic syndrome (MDS) and mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. Br J Haematol. 2005; 128: 649–658
   PubMedGoogle Scholar
• Castro-Malaspina H, Harris R E, Gajewsky J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943–1951
   PubMed Web of Science ®Google Scholar
• Kalwak K, Wójcik D, Gorczynska E, et al. Allogeneic hemopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: Is that an alternative?. Transplant Proc. 2004; 36: 1574–1577
   PubMed Web of Science ®Google Scholar
• Sauter C, Barker J N. Unrelated donor umbilical cord transplantation for the treatment of hematologic malignancies. Curr Opin Hematol. 2008; 15: 568–575
   PubMed Web of Science ®Google Scholar
• Guinan E C, Tarbell N J, Trantavahi R, Weinstein H J. Bone marrow transplantation for children with myelodysplastic syndrome. Blood 1989; 73: 619–623
   PubMed Web of Science ®Google Scholar
• Rune V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treament in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998; 21: 255–261
   PubMedGoogle Scholar
• Anderson J E, Appelbaum F R, Fisher L D, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplatic syndromes. Blood 1993; 82: 677–681
   PubMed Web of Science ®Google Scholar
• Ebb D KH, Passmore S J, Hann I M, et al. Results of treatment of children with refractory anemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-t) in Great Britain, 1990–1999. Br J Haematol 2002; 117: 33–39
   PubMedGoogle Scholar
• Creutzig U, Bender-Gotze C, Ritter J, et al. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia. 1998; 12: 652–659
   PubMedGoogle Scholar
• Niemeyer U, Duffner C, Bender-Gotze C, et al. AML-type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS), (Abstract). Blood 2000; 96: 5212
   Google Scholar
• Skinner R, Velangi M, Bown M. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. Pediatr Blood Cancer 2008; 50: 670–672
   PubMedGoogle Scholar
• Bader P, Niemeyer C, Willasch A, et al. WT1 gene expression: Useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukaemia?. Eur J Haematol 2004; 73: 25–28
   PubMed Web of Science ®Google Scholar
• Perez-Simon J A, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J. Chronic graft–versus-host disease: Pathogenesis and clinical management. Drugs 2006; 66: 1041–1057
   PubMed Web of Science ®Google Scholar
• Baron C, Somogyi R, Greller R D, et al. Predictor of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med. 2007; 4: e23, doi: 10.1371/journal.pmed.0040023
   PubMed Web of Science ®Google Scholar
• Niemeyer C M, Kratz C P. Pediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: Molecular classification and treatment options. Br J Haematol 2008; 140: 610–624
   PubMed Web of Science ®Google Scholar
• Castro-Malaspina H, Jabubowski A A, Papadopoulos E B, et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008; 14: 458–68
   PubMed Web of Science ®Google Scholar
• Strahm B, Locatelli F, Bader P, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 2007; 40: 329–333
   PubMed Web of Science ®Google Scholar